Rindopepimut Significantly Increases Overall Survival of Treatment-Resistant Glioblastoma Patients

Rindopepimut is a vaccine that targets the epidermal growth factor receptor variant III mutation (EGFRvIII), which occurs in 31% of glioblastoma multiforme cases and is linked to poor long-term survival regardless of other factors such as extent of… [Learn More…]